Modern low-molecular-weight heparins in the prevention and treatment of venous thromboembolic complications in oncourologic patients
Oncourologic diseases are accompanied by a risk for subsequent venous thromboembolic complications, which are rated the most dangerous in terms of thrombogenic effect. The article presents a review of the clinical studies of efficacy and safety, and the experience in using of modern low-molecular-we...
| Автори: | , |
|---|---|
| Формат: | Стаття |
| Мова: | Russian |
| Опубліковано: |
Remedium Group LLC
2018-11-01
|
| Серія: | Медицинский совет |
| Предмети: | |
| Онлайн доступ: | https://www.med-sovet.pro/jour/article/view/2756 |
| Резюме: | Oncourologic diseases are accompanied by a risk for subsequent venous thromboembolic complications, which are rated the most dangerous in terms of thrombogenic effect. The article presents a review of the clinical studies of efficacy and safety, and the experience in using of modern low-molecular-weight heparins in clinical practice - drugs of choice for the prevention of venous thromboembolic complications in cancer patients. Particular attention is paid to Bemiparin - a new second-generation low-molecular-weight heparin with a significant antithrombotic effect and improved pharmacological parameters that allow it to be successfully used in patients with impaired renal function in oncourological practice. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |